Minerva Neurosciences, Inc – FDA CRL

Minerva Neurosciences, Inc. received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA 217002) for roluperidone extended-release tablets, indicating the application cannot be approved in its current form. The primary issues identified involve insufficient evidence of effectiveness for treating negative symptoms of schizophrenia. The FDA noted that while one study (C03) met its primary endpoint, a second pivotal study (C07) did not, and post-hoc analyses were deemed insufficient to overcome this. Key deficiencies included a lack of data on roluperidone's safety and efficacy when co-administered with standard antipsychotic medications, a critical component of schizophrenia treatment. Furthermore, the submitted data did not demonstrate that the observed changes in negative symptoms were clinically meaningful, and the long-term safety database was inadequate, falling short of international guidelines for chronic conditions.

From a clinical pharmacology standpoint, the FDA highlighted concerns regarding roluperidone's association with concentration-dependent QTc prolongation. The company's proposed risk mitigation strategy, which relies on CYP2D6 genetic testing, was deemed inappropriate due to inconsistencies with current phenotyping standards and non-standard definitions of metabolizer types, posing potential safety risks for intermediate metabolizers. To address these issues, Minerva must conduct at least one additional robust, well-controlled study demonstrating roluperidone's safety and effectiveness, including data on co-administration with antipsychotics, evidence of clinically meaningful symptom improvement, and comprehensive long-term safety data. The FDA recommends discussing the design of any new studies before initiation.